DENTAL-MONITORING
24.3.2020 18:50:12 CET | Business Wire | Press release
Dental Monitoring announced last week the launch of a simplified version of SmileMate Virtual Consultation - its tele dentistry solution to allow dental professionals to assess their new patient enquiries remotely and in a HIPAA compliant manner.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200324005658/en/
Given the scale of the pandemic, and the increasing containment measures taken by governments worldwide, tele dentistry such as SmileMate Virtual Consultation has emerged as a solution to help assess patients remotely in these unprecedented times - initiating a first consultation from home and preventing the spread of COVID-19.
Standing alongside all dental professionals, Dental Monitoring has now decided to provide until the end of May 2020, free access for SmileMate Virtual Consultation to all individual dentists and orthodontists worldwide.
SmileMate Virtual Consultation is a “light” version of SmileMate, simpler and more immediate to implement for these times - enabling rapid on-boarding and roll-out. It has been developed to allow practices to remotely assess their new patients directly through their website.
CEO and Co-founder of Dental Monitoring, Philippe Salah, explained: “Allowing free access to our solution until the end of May is our duty as global citizens. It is important that we help dental professionals find solutions so they can keep providing their expert care, even during the pandemic .”
On the accelerated development of SmileMate Virtual Consultation, CEO and Founder of SmileMate, Nick Duncan said: “I think I speak for the entire dental industry when I say that our sole focus at this time is to do whatever we can to help clinics get through the current period of uncertainty. We've worked hard to develop a new version of our technology that is easier to implement for both patients and individual clinics. As a partner of dental professionals, making it free for all independent dentists and orthodontists was the right thing to do.”
Dental Monitoring is working with dental professionals, to improve its solutions and help patients access dental care anytime, anywhere.
About SmileMate Virtual Consultation
, remote assessment of new patients.
All new patient calls can be pre-qualified remotely using the SmileMate Virtual Consultation assessment tool directly through the doctor’s practice website. The process is simple:
Step 1 - The doctor simply installs a widget on its practice website. The new patient clicks on the widget, creates a profile and takes five intra-oral pictures on their smartphone (no need to download an App or use a ScanBox and cheek retractors)
Step 2 - A comprehensive customized report is automatically generated by our AI engine and sent to the doctor
Step 3 - The doctor qualifies the patient’s needs on their SmileMate portal
Step 4 - The doctor reviews and personalizes the report before sharing with the patient together with their treatment options and a booking link if an appointment is required.
To implement SmileMate Virtual Consultation, please visit: https://dental-monitoring.com/maintain-patient-care/
After May 31st, 2020, and until the end of the pandemic, SmileMate Virtual Consultation will be available at a reduced 50% cost: US$150/month.
About Fast-Track Accelerated On-Boarding
SmileMate Virtual Consultation is ready for use in minutes after doctors and their teams have performed our free fast-track accelerated onboarding - a new simplified and streamlined implementation process, which is done 100% remotely through webinars and individual support by our customer support team.
To book a time slot for our next training session, please visit: https://dental-monitoring.com/maintain-patient-care/
About Dental Monitoring
(www.dental-monitoring.com
)
Founded in 2015 by Philippe Salah, Dental Monitoring is the first AI-based company addressing the dental market. The DM software suite is designed to address the needs of dental professionals all along the patient journey: before treatment to increase the patient’s engagement, during treatment to improve the quality of care provided by the dental professionals, and after treatment to ensure the stability of the treatment outcome. The company operates in Europe, the United States and Asia-Pacific. It employs around 250 employees across its five offices located in Paris, Austin, London, Hong Kong and Sydney. SmileMate is a subsidiary of Dental Monitoring (https://www.smilemate.com/
).
View source version on businesswire.com: https://www.businesswire.com/news/home/20200324005658/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
New Auction Record Set as Falcon Sells for AED 1.5 Million at ADIHEX 202629.8.2026 23:54:00 CEST | Press release
Qarmousha Pure Ultra White falcon sells for AED 1.5 million at the Abu Dhabi International Hunting and Equestrian Exhibition 2026 (ADIHEX) falcon auction Under the patronage of His Highness Sheikh Hamdan bin Zayed Al Nahyan, Ruler’s Representative in Al Dhafra Region and Chairman of the Emirates Falconers’ Club, the fifth auction held as part of the 23rd edition of the Abu Dhabi International Hunting and Equestrian Exhibition (ADIHEX) 2026 attracted remarkable turnout, culminating in the sale of a Qarmousha Pure Ultra White falcon for AED 1.5 million (USD 408,000). The sale marks the highest price achieved at any auction during this year’s edition of the exhibition. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260829032621/en/ Qarmousha Pure Ultra White (Photo: AETOSWire) This forms part of the largest auction programme in the exhibition’s history, held under the theme “A Legacy of Pride,” organised by ADNEC Group, a Modon
Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera29.8.2026 00:40:00 CEST | Press release
MIMRYLO, a First-in-Class Medicine with a Unique Mechanism of Action, is Approved for the Treatment of Erythrocytosis in Adults with Polycythemia Vera (PV)MIMRYLO Has Been Shown to Maintain Hematocrit Control, the Primary Treatment Goal in PV, as Well as Reduce Phlebotomy Burden and Improve FatigueApproval Supported by Phase 3 VERIFY Results Showing 76.9% of Patients Achieved Clinical Response During Weeks 20-32 Takeda (TSE:4502/NYSE:TAK)announced U.S. Food and Drug Administration (FDA) approval of the New Drug Application (NDA)* for MIMRYLO™ (rusfertide) for the treatment of erythrocytosis in adults with polycythemia vera (PV), a blood cancer. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260824773270/en/ MIMRYLO Logo MIMRYLO is a first-in-class hepcidin mimetic designed to regulate iron distribution in the body and red blood cell overproduction to control hematocrit levels, which is the ratio of red blood cells to the tot
Rigaku and Tohoku University Establish a New Research Institute for X-Ray Metrology28.8.2026 16:00:00 CEST | Press release
Rigaku Corporation, a group company of Rigaku Holdings and a global solutions partner for X-ray analytical systems (Head Office: Akishima, Tokyo; President and CEO: Jun Kawakami; “Rigaku”), and Tohoku University (Sendai, Miyagi; President: Teiji Tominaga; “Tohoku University”) have established the Rigaku-Tohoku University Co-Creation Research Institute for X-ray Metrology: Beyond The Limits (the “Institute”) at Tohoku University on August 1, 2026. The Institute will advance X-ray metrology technology, develop new metrology methods, and foster the next generation of researchers through an initial three-year collaboration, with the possibility of extension based on its achievements. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828688510/en/ Inside the Institute As semiconductors become smaller, more multilayered, and incorporate a wider range of materials, manufacturing processes are becoming increasingly complex. X-ray me
BLK: Portfolio Company of Enry’s Island S.p.A., Lists on Euronext Dublin28.8.2026 15:34:00 CEST | Press release
Enry’s Island S.p.A. (WBAG:EIOS), an international venture builder with headquarters in the Tremiti Islands and the Metaverse, announces that BLK Global PLC, one of the portfolio companies within its ecosystem, has successfully completed its admission to trading on Euronext Access Dublin. Trading in the company’s shares commenced on Friday, July 31, 2026, under ticker BLKX and ISIN GB00BPSKS130. BLK was one of the thousands of applications received by Enry’s Island which, following an assessment process based on the Enry’s Model, was selected for a one-year incubation and acceleration programme. The programme supported the company through its subsequent growth stages, ultimately leading to its current stock market listing. Alessandro Pacciana, Investor Relations Manager of Enry’s Island S.p.A., said: “BLK’s listing is the second stock market listing in two years among Enry’s Island’s portfolio companies, while Enry’s Island itself is the world’s first listed venture builder. We are pro
Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release
Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom